MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.380
-0.020
-1.43%
After Hours: 1.290 -0.09 -6.52% 17:42 02/21 EST
OPEN
1.420
PREV CLOSE
1.400
HIGH
1.429
LOW
1.350
VOLUME
42.20K
TURNOVER
--
52 WEEK HIGH
7.39
52 WEEK LOW
1.190
MARKET CAP
12.60M
P/E (TTM)
-0.6445
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ATOS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATOS stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.

EPS

ATOS News

More
  • Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
  • GlobeNewswire · 02/05 13:00
  • Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day "Transforming Breast Cancer Treatment"
  • ACCESSWIRE · 02/04 22:10
  • Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020
  • GlobeNewswire · 01/22 13:30
  • Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.
  • GlobeNewswire · 01/06 13:00

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ATOS

Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).
More

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.